TEVA · Teva Pharmaceutical Industries Ltd
$37.62
-0.30 (-0.79%)
At close · Aug 27
Market Cap
$44.19B
Shares
1.17B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$17.26B
+4.3%
FY2025
Net Income
$1.41B
+186%
FY2025
Gross Margin
51.79%
+3pp
FY2025
Operating Margin
12.5%
+14.3pp
FY2025
Diluted EPS
$1.21
+183.4%
FY2025
Operating Cash Flow
$1.65B
+32.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $16.5B – $16.85B | $14.1B | $17.26BG | $16.54BG | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B | $21.85B | $21.9B | $19.65B | $20.27B | $20.31B | $20.32B | $18.31B | $16.12B | $16.12B | $11.09B | $9.41B | |
| — | $8.23B | $8.32B | $8.48B | $8.2B | $7.95B | $8.28B | $8.93B | $9.35B | $9.98B | $11.24B | $10.25B | $8.3B | $9.22B | $9.61B | $9.67B | $8.8B | $7.06B | $6.53B | $5.12B | $4.53B | |
| — | $9.08B | $8.94B | $8.06B | $7.65B | $6.97B | $7.59B | $7.73B | $7.54B | $8.3B | $10.62B | $11.65B | $11.36B | $11.06B | $10.71B | $10.65B | $9.52B | $9.07B | $7.37B | $5.97B | $4.88B | |
| — | — | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% | 46.38% | 44.63% | 45.41% | 48.57% | 53.2% | 57.79% | 54.54% | 52.71% | 52.43% | 51.96% | 56.23% | 45.7% | 53.84% | 51.84% | |
| — | $1.71B | $1.01B | $998M | $953M | $98M | $967M | $997M | $1.01B | $114M | $175M | $422M | $35M | $0 | $5M | $73M | $15M | $951M | $825M | $786M | $581M | |
| — | $2.82B | $2.69B | $2.54B | $2.34B | $2.27B | $2.43B | $2.5B | $2.61B | $2.92B | $3.4B | $3.58B | $3.48B | $3.86B | $4.08B | $3.88B | $3.48B | $2.97B | $2.68B | $1.84B | $1.26B | |
| — | $1.31B | $1.29B | $1.16B | $1.16B | $1.18B | $1.1B | $1.17B | $1.19B | $1.3B | $1.45B | $1.39B | $1.36B | $1.22B | $1.24B | $1.24B | $932M | $865M | $823M | $669M | $637M | |
| — | $564M | $581M | $588M | $616M | $732M | $802M | $1.02B | $1.11B | $1.17B | $1.44B | $993M | $838M | $1.04B | $1.18B | $1.27B | $707M | — | — | — | — | |
| — | $987M | $1B | $1.06B | $1.15B | $1.31B | $1.33B | $1.56B | $1.72B | $1.84B | $2.11B | $1.52B | $1.31B | $1.51B | $1.64B | $1.71B | $1.07B | $977M | $908M | $490M | $499M | |
| — | $120M | $225M | $74M | $111M | $146M | $133M | $120M | $199M | $488M | $535M | $245M | $183M | $246M | $201M | $221M | $192M | $260M | $90M | $0 | — | |
| — | $1.6B | $2.16B | -$303M | $433M | -$2.2B | $1.72B | -$3.57B | -$443M | -$1.64B | -$17.48B | $2.15B | $3.35B | $3.95B | $1.65B | $2.21B | $3.11B | $3.87B | $2.41B | $1.15B | $2.4B | |
| — | — | 12.5% | -1.83% | 2.73% | -14.72% | 10.81% | -21.44% | -2.62% | -8.96% | -80.01% | 9.83% | 17.06% | 19.49% | 8.12% | 10.85% | 16.98% | 24.01% | 14.92% | 10.33% | 25.46% | |
| — | $2.59B | $3.16B | $756M | $1.59B | -$889M | $3.05B | -$2.02B | $1.28B | $205M | -$15.37B | $3.68B | $4.66B | $5.46B | $3.29B | $3.91B | $4.18B | $4.85B | $3.31B | $1.64B | $2.89B | |
| — | — | $916M | $1B | $1.03B | $930M | $891M | $901M | $822M | $920M | $875M | $546M | $270M | $300M | $314M | $355M | $234M | $202M | $230M | $201M | — | |
| — | -$897M | -$934M | -$981M | -$1.06B | -$966M | -$1.06B | -$834M | -$822M | -$959M | -$895M | -$1.33B | -$1B | -$313M | -$399M | -$386M | -$153M | -$225M | -$202M | -$345M | -$91M | |
| — | — | $15M | $1M | $2M | $21M | $9M | $138M | -$13M | -$71M | -$3M | $8M | -$121M | -$5M | -$40M | -$46M | -$61M | -$24M | -$33M | -$1M | -$3M | |
| — | $708M | $1.22B | -$1.28B | -$624M | -$3.16B | $658M | -$4.41B | -$1.27B | -$2.6B | -$18.38B | $824M | $2.35B | $3.64B | $1.25B | $1.82B | $2.96B | $3.65B | $2.2B | $800M | $2.3B | |
| — | $12M | -$180M | $676M | -$7M | -$643M | $211M | -$168M | -$278M | -$195M | -$1.93B | $521M | $634M | $591M | -$43M | -$137M | $127M | $283M | $166M | $184M | $386M | |
| — | $707M | $1.41B | -$1.64B | -$559M | -$2.45B | $417M | -$3.99B | -$999M | -$2.15B | -$16.27B | $329M | $1.59B | $3.06B | $1.27B | $1.96B | $2.76B | $3.33B | $2B | $609M | $1.91B | |
| — | — | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% | -23.95% | -5.92% | -11.77% | -74.43% | 1.5% | 8.08% | 15.07% | 6.25% | 9.66% | 15.07% | 20.66% | 12.41% | 5.49% | 20.34% | |
| — | — | $7M | -$320M | -$56M | -$53M | $39M | -$109M | -$2M | -$322M | -$184M | -$18M | $9M | -$13M | -$16M | -$53M | $9M | $8M | $4M | $6M | $1M | |
| — | — | — | — | — | — | — | -$3.99B | -$999M | -$2.4B | -$16.53B | $68M | $1.57B | $3.06B | $1.27B | — | — | — | — | — | — | |
| — | $674M | $2.17B | -$2.09B | -$418M | -$2.6B | $133M | -$4.08B | -$852M | -$2.76B | -$14.96B | -$875M | $984M | $1.78B | $1.18B | $2.48B | $1.83B | $3.13B | — | — | — | |
| USD/shares | — | $0.62 | $1.23 | -$1.45 | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | -$16.26 | $0.07 | $1.84 | $3.58 | $1.49 | $2.25 | $3.10 | $3.72 | $2.29 | $0.78 | $2.49 |
| USD/shares | $1.91 – $2.11* | $0.61 | $1.21G | -$1.45G | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | -$16.26 | $0.07 | $1.82 | $3.56 | $1.49 | $2.25 | $3.09 | $3.67 | $2.23 | $0.75 | $2.36 |
| shares | — | — | 1.15B | 1.13B | 1.12B | 1.11B | 1.1B | 1.1B | 1.09B | 1.02B | 1.02B | 955 | 855M | 853M | 849M | 872M | 890M | 896M | 872M | 780M | 768M |
| shares | — | — | 1.16B | 1.13B | 1.12B | 1.11B | 1.11B | 1.1B | 1.09B | 1.02B | 1.02B | 961 | 864M | 858M | 850M | 873M | 893M | 921M | 896M | 820M | 830M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2018: $3.75B in buybacks, $9.15B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.68×
EV/EBIT
—
Peer median 21.74×
P/E (TTM)
62.16×
Peer median 24.17×
Peer medians compare against the 11 similar-size Drug Manufacturers - Specialty & Generic companies (of 102 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States Segment | $9,186,000,000 | $8,034,000,000 | $7,731,000,000 | $7,003,000,000 | — | — | — | — |
| Europe Segment | $5,040,000,000 | $5,103,000,000 | $4,837,000,000 | $4,525,000,000 | $4,886,000,000 | $4,757,000,000 | $4,795,000,000 | $5,186,000,000 |
| International Markets | $2,162,000,000 | $2,463,000,000 | $2,351,000,000 | $2,352,000,000 | $2,032,000,000 | $2,154,000,000 | $2,246,000,000 | $2,422,000,000 |
| Other Activities | $870,000,000 | $944,000,000 | $926,000,000 | $1,045,000,000 | $1,151,000,000 | $1,302,000,000 | $1,304,000,000 | $1,366,000,000 |
| North America Segment | — | — | — | — | $7,809,000,000 | $8,447,000,000 | $8,542,000,000 | $9,297,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $9,186,000,000 | $8,034,000,000 | $7,731,000,000 | $7,003,000,000 | — | — | — | — |
| Europe | $5,040,000,000 | $5,103,000,000 | $4,837,000,000 | $4,525,000,000 | $4,886,000,000 | $4,757,000,000 | $4,795,000,000 | $5,186,000,000 |
| North America | — | — | $8,124,000,000 | $7,452,000,000 | $7,809,000,000 | $8,447,000,000 | $8,542,000,000 | $9,297,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $14,605,000,000 | $14,050,000,000 | $12,979,000,000 | $12,766,000,000 | $13,829,000,000 | $14,354,000,000 | $14,510,000,000 | $15,881,000,000 |
| Distribution Service | $1,551,000,000 | $1,576,000,000 | $1,615,000,000 | $1,519,000,000 | $1,390,000,000 | $1,495,000,000 | $1,514,000,000 | $1,373,000,000 |
| License | $678,000,000 | $173,000,000 | $681,000,000 | $212,000,000 | $160,000,000 | $129,000,000 | $147,000,000 | $165,000,000 |
| Product And Service Other | $423,000,000 | $745,000,000 | $570,000,000 | $428,000,000 | $500,000,000 | $680,000,000 | $716,000,000 | $852,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Corporate | $4,995,000,000 | $4,311,000,000 | $4,338,000,000 | $3,968,000,000 | $4,246,000,000 | $4,225,000,000 | $4,034,000,000 | $4,608,000,000 |
| United States Segment | $3,356,000,000 | $2,296,000,000 | $2,394,000,000 | $1,934,000,000 | — | — | — | — |
| Europe Segment | $1,303,000,000 | $1,575,000,000 | $1,478,000,000 | $1,496,000,000 | $1,494,000,000 | $1,331,000,000 | $1,318,000,000 | $1,273,000,000 |
| International Markets | $336,000,000 | $440,000,000 | $465,000,000 | $538,000,000 | $529,000,000 | $474,000,000 | $464,000,000 | $498,000,000 |
| All Other Segments | -$90,000,000 | $18,000,000 | $24,000,000 | $172,000,000 | $154,000,000 | $163,000,000 | $108,000,000 | $115,000,000 |
| North America Segment | — | — | $2,396,000,000 | $1,993,000,000 | $2,224,000,000 | $2,421,000,000 | $2,252,000,000 | $2,837,000,000 |
| Segments and Other Activities | — | — | $4,361,000,000 | $4,139,000,000 | $4,401,000,000 | $4,388,000,000 | $4,142,000,000 | $4,723,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States Segment | 36.5% | 28.6% | 31% | 27.6% | — | — | — | — |
| Europe Segment | 25.9% | 30.9% | 30.6% | 33.1% | 30.6% | 28% | 27.5% | 24.5% |
| International Markets | 15.5% | 17.9% | 19.8% | 22.9% | 26% | 22% | 20.7% | 20.6% |
| North America Segment | — | — | — | — | 28.5% | 28.7% | 26.4% | 30.5% |
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
498 filings
497 filers
Visit website
Investor relations